Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

161. Effectiveness of proton pump inhibitors in nonerosive reflux disease

Effectiveness of proton pump inhibitors in nonerosive reflux disease Effectiveness of proton pump inhibitors in nonerosive reflux disease Effectiveness of proton pump inhibitors in nonerosive reflux disease Dean B B, Gano A D, Knight K, Ofman J J, Fass R CRD summary This review assessed the use of proton-pump inhibitors (PPIs) to relieve the symptoms of nonerosive reflux disease (NERD). The authors concluded that PPIs have a lesser effect in NERD than in erosive oesophagitis, and that symptoms (...) tended to improve throughout the 4-week period. Insufficient data were presented to assess the appropriateness of pooling the studies, hence any conclusions may not be reliable. Authors' objectives To assess the effectiveness of proton-pump inhibitors (PPIs) for the relief of symptoms of nonerosive reflux disease (NERD), and also to assess the effects of PPIs in patients with NERD compared with patients with erosive oesophagitis (EE). Searching MEDLINE and HealthSTAR were searched for studies

2004 DARE.

162. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics

Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics Numans M E, Lau J, de Wit N J, Bonis P A CRD summary (...) This review assessed the accuracy of symptomatic response to proton-pump inhibitor (PPI) treatment in the diagnosis of gastroesophageal reflux disease (GERD). The authors concluded that a response to short-term treatment with PPIs does not accurately diagnose GERD as defined by traditional objective criteria. The authors' conclusions are likely to be reliable. Authors' objectives To determine the diagnostic accuracy of symptomatic response to proton-pump inhibitor (PPI) treatment as an indicator

2004 DARE.

163. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis

The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis Moayyedi P, Delaney B C, Vakil N, Forman D, Talley N J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of proton-pump inhibitors (PPIs) in adult patients with nonulcer dyspepsia (NUD). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical cohort of adult patients with symptoms of dyspepsia, negative findings on endoscopy

2004 NHS Economic Evaluation Database.

164. Cost-effectiveness of proton pump inhibitor therapy for acute peptic ulcer-related bleeding

Cost-effectiveness of proton pump inhibitor therapy for acute peptic ulcer-related bleeding Cost-effectiveness of proton pump inhibitor therapy for acute peptic ulcer-related bleeding Cost-effectiveness of proton pump inhibitor therapy for acute peptic ulcer-related bleeding Erstad B L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study evaluated the use of adjunctive oral and intravenous proton-pump inhibitor (PPI) therapies for patients with acute peptic ulcer-related bleeding of sufficient severity to warrant hospitalisation. Four clinical scenarios were considered. Scenario 1 was diagnostic endoscopy and oral PPI therapy (40 mg twice daily of omeprazole or the equivalent dose of another PPI for 5 days). Scenario 2

2004 NHS Economic Evaluation Database.

165. Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use

Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use Klok R M, Postma M J, Van Hout B A, Brouwers J R CRD summary This review compared the effectiveness of different proton-pump inhibitors in the management of gastro-oesophageal reflux disease, peptic ulcer disease and Heliocobacter pylori. The authors (...) concluded that the differences found may be due to the high dose used and not the specific inhibitor. Given the lack of information on differences between the studies and the quality of the individual studies, it is difficult to verify the conclusions. Authors' objectives To compare the efficacy of proton-pump inhibitors (PPIs) in the short-term management of gastro-oesophageal reflux disease (GERD), peptic ulcer disease PUD), and the eradication of Helicobacter pylori (H. pylori). Searching MEDLINE

2003 DARE.

166. Meta-analysis. Proton pump inhibitors vs. H2-receptor antagonists: their efficacy with antibiotics in Helicobacter pylori eradication

Meta-analysis. Proton pump inhibitors vs. H2-receptor antagonists: their efficacy with antibiotics in Helicobacter pylori eradication Meta-analysis. Proton pump inhibitors vs. H2-receptor antagonists: their efficacy with antibiotics in Helicobacter pylori eradication Meta-analysis. Proton pump inhibitors vs. H2-receptor antagonists: their efficacy with antibiotics in Helicobacter pylori eradication Gisbert J P, Khorrami S, Calvet X, Gabriel R, Carballo F, Pajares J M CRD summary This meta (...) -analysis assessed the effectiveness of proton-pump inhibitors and H2-receptor antagonists, both co-prescribed with antibiotics, in Helicobacter pylori eradication. The authors concluded that proton-pump inhibitors are more effective than H2-receptor antagonists when prescribed at usual doses. The authors' conclusion is consistent with the evidence reviewed, and is likely to be reliable. Authors' objectives To perform a meta-analysis comparing the efficacy of proton-pump inhibitors (PPIs) and H2

2003 DARE.

167. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication

Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication Vergara M, Vallve M, Gisbert J P, Calvet X CRD summary This review compared the efficacy of different proton-pump (...) inhibitors (omeprazole, lansoprazole, rabeprazole and esomeprazole) in standard triple therapy for Helicobacter pylori eradication. The authors concluded that there appears to be no difference in the efficacy of different proton-pump inhibitors. The authors' conclusions are likely to be reliable. Authors' objectives To compare the efficacy of different proton-pump inhibitors (PPIs) in triple therapy for Helicobacter pylori (H. pylori) eradication. Searching MEDLINE was searched in September 2002

2003 DARE.

168. Systematic review: direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease

Systematic review: direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease Systematic review: direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease Systematic review: direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer (...) disease Vakil N, Fennerty M B CRD summary This review assessed the efficacy of proton-pump inhibitors in treating gastro-oesophageal reflux and peptic ulcer disease, and concluded that insufficient evidence was available to establish the superiority of any one agent. A limited search and language restrictions mean that studies might have been missed. The broad conclusion seems appropriate, however, the specific conclusions and implications for practice should be treated with caution. Authors

2003 DARE.

169. Low-dose or standard-dose proton pump inhibitors for maintenance therapy of gastro-oesophageal reflux disease: a cost-effectiveness analysis

Low-dose or standard-dose proton pump inhibitors for maintenance therapy of gastro-oesophageal reflux disease: a cost-effectiveness analysis Low-dose or standard-dose proton pump inhibitors for maintenance therapy of gastro-oesophageal reflux disease: a cost-effectiveness analysis Low-dose or standard-dose proton pump inhibitors for maintenance therapy of gastro-oesophageal reflux disease: a cost-effectiveness analysis You J H, Lee A C, Wong S C, Chan F K Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared standard-dose histamine-2 receptor antagonist (H2RA), low-dose proton-pump inhibitor (PPI) and standard-dose PPI as maintenance therapy in patients with gastrooesophageal reflux disease (GERD

2003 NHS Economic Evaluation Database.

170. Cost-effectiveness in Canada of intravenous proton pump inhibitors for all patients presenting with acute upper gastrointestinal bleeding

Cost-effectiveness in Canada of intravenous proton pump inhibitors for all patients presenting with acute upper gastrointestinal bleeding Cost-effectiveness in Canada of intravenous proton pump inhibitors for all patients presenting with acute upper gastrointestinal bleeding Cost-effectiveness in Canada of intravenous proton pump inhibitors for all patients presenting with acute upper gastrointestinal bleeding Enns R A, Gagnon Y M, Rioux K P, Levy A R Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology An approach in which an intravenous (i.v.) proton-pump inhibitor (PPI), such as pantoprazole, was administered before endoscopy treatment was examined in patients with upper gastrointestinal (GI) bleeding. Type of intervention

2003 NHS Economic Evaluation Database.

171. Proton pump inhibitors versus H2 antagonists or placebo in treating bleeding peptic ulcer

Proton pump inhibitors versus H2 antagonists or placebo in treating bleeding peptic ulcer Proton pump inhibitors versus H2 antagonists or placebo in treating bleeding peptic ulcer Proton pump inhibitors versus H2 antagonists or placebo in treating bleeding peptic ulcer Abdulwadud O Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Abdulwadud O. Proton pump (...) inhibitors versus H2 antagonists or placebo in treating bleeding peptic ulcer. Clayton, Victoria: Centre for Clinical Effectiveness (CCE) 2002: 11 Authors' objectives This aim of this critical appraisal was to assess the effectiveness of proton pump inhibitors versus H2 antagonists or placebo in treating bleeding peptic ulcer. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Anti-Ulcer Agents; Peptic Ulcer /drug therapy; Proton Pumps Language Published English Country

2002 Health Technology Assessment (HTA) Database.

172. The efficacy of proton pump inhibitors in adults with functional dyspepsia

The efficacy of proton pump inhibitors in adults with functional dyspepsia The efficacy of proton pump inhibitors in adults with functional dyspepsia The efficacy of proton pump inhibitors in adults with functional dyspepsia Shiau J Y, Shukla V K, Dube C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Shiau J Y, Shukla V K, Dube C (...) . The efficacy of proton pump inhibitors in adults with functional dyspepsia. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2002: 30 Authors' objectives Primary objective: To determine the efficacy of PPIs in the reduction of symptoms in adults with functional dyspepsia compared with placebo, prokinetic agents and H2-antagonists. Secondary objectives: - to determine if the effect of PPIs differs between symptom subgroups (dysmotility-like, or ulcer-like) in functional

2002 Health Technology Assessment (HTA) Database.

173. Are proton pump inhibitors the first choice for acute treatment of gastric ulcers: a meta analysis of randomized clinical trials

Are proton pump inhibitors the first choice for acute treatment of gastric ulcers: a meta analysis of randomized clinical trials Are proton pump inhibitors the first choice for acute treatment of gastric ulcers: a meta analysis of randomized clinical trials Are proton pump inhibitors the first choice for acute treatment of gastric ulcers: a meta analysis of randomized clinical trials Salas M, Ward A, Caro J Authors' objectives To compare gastric ulcer healing rates for patients treated (...) with a proton-pump inhibitor (PPI), an histamine 2-receptor antagonist or placebo. Searching MEDLINE, and the Cochrane Library were searched using the following keywords: 'proton pump inhibitors', 'PPI', 'rabeprazole', 'omeprazole' 'esomeprazole', 'lansoprazole' 'pantoprazole', 'ranitidine'; 'healing rates', 'gastric ulcer', 'stomach ulcer', 'gastric ulcer disease', 'peptic ulcer', 'peptic related disorders'; and 'clinical trials', 'randomized clinical trials' and 'multicenter studies'. In addition, medical

2002 DARE.

174. Systematic review of proton pump inhibitors for the maintenance of healed reflux oesophagitis

Systematic review of proton pump inhibitors for the maintenance of healed reflux oesophagitis Systematic review of proton pump inhibitors for the maintenance of healed reflux oesophagitis Systematic review of proton pump inhibitors for the maintenance of healed reflux oesophagitis Edwards S J, Lind T, Lundell L Authors' objectives To compare the efficacy of lansoprazole with all other proton-pump inhibitors (PPIs) in the maintenance of healed reflux oesophagitis, through a systematic review (...) but who are concerned about the cost implications of prescribing a standard-dose PPI. Reviewer's comment: Two of the authors were from AstraZeneca, the manufacturer of esomeprazole. Research: The authors state that a cost-effectiveness analysis would need to be undertaken to determine whether the increase in effect represents good value for money. Bibliographic details Edwards S J, Lind T, Lundell L. Systematic review of proton pump inhibitors for the maintenance of healed reflux oesophagitis. Journal

2002 DARE.

175. Cost-effectiveness analysis of proton pump inhibitors compared to omeprazole in the healing of reflux oesophagitis

Cost-effectiveness analysis of proton pump inhibitors compared to omeprazole in the healing of reflux oesophagitis Cost-effectiveness analysis of proton pump inhibitors compared to omeprazole in the healing of reflux oesophagitis Cost-effectiveness analysis of proton pump inhibitors compared to omeprazole in the healing of reflux oesophagitis Plumb J M, Edwards S J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of esomeprazole (40 mg), a proton-pump inhibitor (PPI), in the treatment of gastro-oesophageal reflux disease (GORD). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical cohort of patients requiring treatment for GORD

2002 NHS Economic Evaluation Database.

176. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis

Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis Vallve M, Vergara M, Gisbert J P, Calvet X Authors' objectives To compare the efficacy of a single versus double dose of a proton-pump (...) the results of studies of triple therapy using clarithromycin and metronidazole as second-line therapy before recommending otherwise promising schedules (due to concerns about drug resistance in H. pylori status). Bibliographic details Vallve M, Vergara M, Gisbert J P, Calvet X. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Alimentary Pharmacology and Therapeutics 2002; 16(6): 1149-1156 PubMedID Indexing Status Subject indexing

2002 DARE.

177. Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies

Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand (...) by a grant from AstraZeneca, Molndal, Sweden. Bibliographic details Wahlqvist P, Junghard O, Higgins A, Green J. Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies. PharmacoEconomics 2002; 20(4): 267-277 PubMedID Other publications of related interest Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different

2002 NHS Economic Evaluation Database.

178. Proton pump inhibitors update

Proton pump inhibitors update Proton pump inhibitors update Proton pump inhibitors update Halas C Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Halas C. Proton pump inhibitors update. University HealthSystem Consortium (UHC). Drug Monograph. 2001 Authors' objectives The UHC Drug Monographs are a continuing series of authoritative, concise evaluations of new (...) . Each monograph includes comprehensive information from the primary literature and provides recommendations for appropriate use. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Digestive System Diseases; Proton Pump Inhibitors Language Published English Country of organisation United States Address for correspondence University HealthSystem Consortium, 2001 Spring Rd., Suite 700, Oak Brook, IL 60523 USA. Tel: 630-954-1700; Fax: 630-954-4730; Email: travis@uhc.edu

2001 Health Technology Assessment (HTA) Database.

179. Impact of a formulary change in proton pump inhibitors on health care costs and patients' symptoms

Impact of a formulary change in proton pump inhibitors on health care costs and patients' symptoms Impact of a formulary change in proton pump inhibitors on health care costs and patients' symptoms Impact of a formulary change in proton pump inhibitors on health care costs and patients' symptoms Raisch D W, Klaurens L M, Hayden C, Malagon I, Pulliam G, Fass R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two proton-pump inhibitors, lansoprazole and omeprazole, were studied. No further details were given. Type of intervention Other: Impact of a formulary change that concerned treatments. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients in the study setting who

2001 NHS Economic Evaluation Database.

180. A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole

A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole A systematic comparison of triple therapies for treatment of Helicobacter pylori (...) infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole Janssen M J, Van Oijen A H, Verbeek A L, Jansen J B, De Boer W A Authors' objectives To evaluate whether there is a difference in the efficacy between triple therapies with proton-pump inhibitor (PPI) or ranitidine bismuth citrate (RBC) plus clarithromycin and either amoxicillin or a nitroimidazole, for the treatment of Helicobacter pylori (H. pylori) infection. Searching

2001 DARE.